Commencement of Phase 1 Clinical Trial studying MYMD-1

July 6, 2019
Tampa, Florida- July 6, 2019- MYMD™ Pharmaceuticals, Inc. announced the commencement of its Phase 1 Clinical Trial studying MYMD-1, the ...

MYMD-1, a Novel Immunometabolic Regulator, Ameliorates Autoimmune Thyroiditis via Suppression of Th1 Responses and TNF-α Release

March 2, 2019
MYMD-1 is a synthetic derivative of tobacco alkaloids, compounds that possess immunoregulatory properties and have been linked to the epidemiological ...